


**Amendments to the Claims**

Claims 1-4 (cancelled)

5. (currently amended) A method for the treatment of agitation a disease selected from the group consisting of agitation, behavioral agitation and Alzheimer's disease in a subject in need of such treatment, which comprises administering to said subject a therapeutically effective amount of a compound of formula I




wherein (a)  $\text{R}_1$  and  $\text{R}_2$  together form an oxy group or (b)  $\text{R}_1$  is hydrogen and  $\text{R}_2$  is hydroxy or acetoxy,  
or a pharmaceutically acceptable salt thereof.

6. (original) The method according to claim 5, wherein the compound of formula I is oxcarbazepine.

7. (original) The method according to claim 5, wherein the disease is behavioral agitation.

8. (original) The method according to claim 5, wherein the subject to be treated is diagnosed to have Alzheimer's disease.

9. (original) . A combination comprising (a) a compound of formula I



wherein (a)  $\text{R}_1$  and  $\text{R}_2$  together form an oxy group or (b)  $\text{R}_1$  is hydrogen and  $\text{R}_2$  is hydroxy or acetoxy,

and (b) at least one compound selected from the group consisting of nootropic plant extracts, calcium antagonists, cholinesterase inhibitors, dihydroergotoxin, nicergoline, piracetame, purine derivates, pyritinol, vincamine and vincocetine, in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier.

10. (original) Combination according to claim 9, wherein the compound (b) is a cholinesterase inhibitor.

11. (cancelled).

12. (currently amended) A commercial package comprising a combination according to claim 9 or 10 together with instructions for simultaneous, separate or sequential use thereof in the treatment of agitation in dementia patients.